Title |
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients
|
---|---|
Published in |
Psychopharmacology, March 2014
|
DOI | 10.1007/s00213-014-3515-4 |
Pubmed ID | |
Authors |
Matea Nikolac Perkovic, Gordana Nedic Erjavec, Maja Zivkovic, Marina Sagud, Suzana Uzun, Alma Mihaljevic-Peles, Oliver Kozumplik, Dorotea Muck-Seler, Nela Pivac |
Abstract |
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system. There are mixed reports about the association between the BDNF Val66Met polymorphism, schizophrenia, and treatment response to antipsychotic drugs. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | 2% |
Croatia | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 16% |
Other | 7 | 14% |
Researcher | 7 | 14% |
Student > Ph. D. Student | 6 | 12% |
Professor > Associate Professor | 3 | 6% |
Other | 12 | 24% |
Unknown | 8 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 25% |
Neuroscience | 6 | 12% |
Agricultural and Biological Sciences | 6 | 12% |
Psychology | 5 | 10% |
Nursing and Health Professions | 2 | 4% |
Other | 6 | 12% |
Unknown | 13 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2022.
All research outputs
#6,403,199
of 22,747,498 outputs
Outputs from Psychopharmacology
#1,840
of 5,339 outputs
Outputs of similar age
#61,283
of 221,294 outputs
Outputs of similar age from Psychopharmacology
#25
of 62 outputs
Altmetric has tracked 22,747,498 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 5,339 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 221,294 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.